

## MELANOMA BRIDGE

December 1<sup>st</sup> – 3<sup>rd</sup> 2022

### SCIENTIFIC RATIONAL

Recent insights into the genetic and somatic aberrations have initiated a new era of rapidly evolving treatments for melanoma.

The possibility to use targeted and immune-based drugs alone, in combination, or in sequence, able to improve responses to overcome the resistance, to potentiate the action of immune system with the new immunomodulating antibodies, and identification of biomarkers that can predict the response to a particular therapy, represent actual concepts and approaches in the clinical management of melanoma.

Melanoma treatment landscape changed in 2011 with the approval of the first anti-cytotoxic T-lymphocyte-associated protein (CTLA)-4 checkpoint inhibitor and of the first BRAF-targeted monoclonal antibody, both of which significantly improved overall survival.

Since then, improved understanding of the tumor microenvironment and tumor immuno-evasion strategies has resulted in different approaches to target and harness the immune response.

Approval of new immune- and target-therapies have further improved outcomes for patients with advanced melanoma.

The therapies offer the opportunity for various approaches with distinct modes of action being used in combination with one another, as well as combined with other treatment modalities such as radiotherapy, electrochemotherapy and surgery.

This year latest findings in melanoma research and advances on themes of paramount importance for melanoma prevention, diagnosis and treatment, will be discussed in the session dedicated to system biology on immunotherapy, immunogenicity and gene expression profiling and focused on the progresses of melanoma research on biomarkers/precision medicine and on combination strategies.

Then, the “Great Debate” sessions, where counterpoint views from leading experts on specific and very actual controversial clinical issues will be presented and discussed from different points of view.

In order to disclose and stimulate the discussion of new approaches and strategies in the field of melanoma and, based on the increasing success of “Melanoma Bridge” events over the years since 2011, a panel of international faculty will join the congress that will be held in Naples in December 2022.

Presidents of the event are Paolo A. Ascierto (National Cancer Institute, “Fondazione G. Pascale”, Naples, Italy), Iman Osman (New York University School of Medicine, New York, NY, USA), Igor Puzanov (Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA) and Corrado Caracò (National Cancer Institute, “Fondazione G. Pascale”, Naples, Italy), who will gather with the international faculty members in an interactive atmosphere which stimulates discussion and exchange of their experience regarding the most recent advances in research and clinical management of melanoma patients.



**3P Solution S.r.l.** a socio unico.

Sede Legale: Corso Magenta 81, 20123 Milano.

Capitale sociale: 10.000,00€ iv. P.IVA/CF 06860060968 Iscrizione REA MI n.1919426.

Provider Standard n. 327 dal 15 ottobre 2012 - Sistema di gestione per la qualità secondo la Norma

UNI EN ISO 9001:2015 per progettazione ed erogazione dei servizi per la Formazione Continua in Sanità.

Certificazione CSQA n. 23887

## PRELIMINARY SCIENTIFIC PROGRAM

*\*Invited speaker*

*\*\*Not included on CME accredited program*

### December 1<sup>st</sup>, 2022 - Thursday

#### **Melanoma Bridge Opening Session\*\***

**Chairpersons:** Paolo A. Ascierto, Francesco Marincola

19:00 19:10 Melanoma Awards

19:10 19:30 Lecture: Climbing out of the trough of disillusionment in the efficacy of radiation therapy and immunotherapy combinations\*\*, *Sandra Demaria*

19:30 19:50 Lecture: How are we going to incorporate LAG3 blockade in melanoma? \*\*, *Michael A. Postow*

19:50 20:10 Lecture\*\*, *Francesco Marincola*

### December 2<sup>nd</sup>, 2022 - Friday

09:30 09:35 Introduction and objectives, *Paolo A. Ascierto*

#### **SESSION – Melanoma is model for cancer research**

**Chairpersons:** Giuseppe Masucci, Magdalena Thurin

09:35 09:50 Title to be defined, *Bernard A. Fox*

09:50 10:05 Can we predict response and toxicity to ICI with a single approach? *Iman Osman*

10:05 10:20 Survivorship, Challenges in the Immune Checkpoint Inhibitor era, *Marc S. Ernstoff*

10:20 10:35 Immunotherapy of uveal melanoma, *Soldano Ferrone*

10:35 10:50 Discussion LIVE

10:50 11:05 Deciphering mechanisms of response and resistance to Treg depletion to inform new rational combinations, *Sergio Quezada*

11:05 11:20 Microbiome, *Laurence Zitvogel*

11:20 11:35 Title to be defined, *Jeffrey Gershenwald*

11:35 11:50 Loco-regional treatments for melanoma, *Corrado Caracò*

11:50 12:05 Discussion LIVE

#### **12:05 12:55 SYMPOSIUM – Target Therapy**

**12:55 13:55 Lunch\*\***



**3P Solution S.r.l.** a socio unico.

Sede Legale: Corso Magenta 81, 20123 Milano.

Capitale sociale: 10.000,00€ iv. P.IVA/CF 06860060968 Iscrizione REA MI n.1919426.

Provider Standard n. 327 dal 15 ottobre 2012 - Sistema di gestione per la qualità secondo la Norma

UNI EN ISO 9001:2015 per progettazione ed erogazione dei servizi per la Formazione Continua in Sanità.

Certificazione CSQA n. 23887

**13:55 14:45 SYMPOSIUM – Adjuvant Therapy in Melanoma**

**SESSION – LESS IS MORE: Critical issues in clinical practice**

**Chairpersons:** Alexander Eggermont, Jeffrey Sosman

- 14:45 15:00 Less is more with Immunoscore, *Jerome Galon*
- 15:00 15:15 Title to be defined, *Olivier Michielin*
- 15:05 15:20 Role of adrenergic blockade in the immunotherapy efficacy, *Igor Puzanov*
- 15:20 15:35 Title to be defined, *Georgina Long\**
- 15:35 15:50 Genomics of therapy-resistant melanoma and translational opportunities, *Roger Lo*
- 15:50 16:05 Trials to decrease toxicity and augment the benefit of combination checkpoint inhibition, *Jeffrey Weber*
- 16:05 16:20 Title to be confirmed, *Michelle Krogsgaard*
- 16:20 16:50 Discussion LIVE

**SESSION - GREAT DEBATE**

**Chairpersons:** Paolo A. Ascierto, Corrado Caracò, Iman Osman, Igor Puzanov

- 16:50 17:20 LAG3 VS IPI sequencing  
*Hussein Tawbi VS Omid Hamid*
- 17:20 17:30 Discussion LIVE
- 17:30 18:00 Is anti-PD1 still acceptable as comparator arm? Yes or no  
*Michael Atkins VS Jeffrey Sosman*
- 18:00 18:10 Discussion LIVE

**December 3<sup>rd</sup>, 2022 - Saturday**

**SESSION – GREAT DEBATE**

**Chairpersons:** Paolo A. Ascierto, Corrado Caracò, Iman Osman, Igor Puzanov, Alessandro Testori

- 09:30 10:00 Adjuvant VS neoadjuvant approach for resectable stage III/IV  
*Axel Hauschild VS Christian Blank*
- 10:00 10:10 Discussion LIVE
- 10:10 10:40 Any role for surgery?  
*Alexander M. Eggermont VS Jean-Jacques Grob\**
- 10:40 10:50 Discussion LIVE
- 10:50 11:20 Stage II adjuvant: is there space for locoregional approaches? Yes or No  
*Jason J. Luke VS Janice Menhert*
- 11:20 11:30 Discussion LIVE



**11:30 11:40 Coffee break\*\***

**11:40 12:30 SYMPOSIUM – adjuvant**

**12:30 13:20 SYMPOSIUM – target therapy**

*Paolo A. Ascierto, Reinhard Dummer\**

**13:20 14:20 Lunch\*\***

**SESSION - Emergent strategies**

**Chairpersons:** Nicola Normanno, Giuseppe Palmieri

14:20 14:35 Identification of high-risk melanoma patients with gene expression profiling assays,  
*Claus Garbe*

14:35 14:50 T cell dysfunctional metabolic programming affects checkpoint inhibition efficacy in  
Melanoma, *Brian Gastman*

14:50 15:05 Modulating the liver immune microenvironment for the treatment of uveal melanoma,  
*Richard Carvajal*

15:05 15:20 title to be confirmed, *Thomas Gajewski*

15:20 15:35 TIL Therapy in Melanoma: The Future is Now, *Allison Betof-Warner*

15:35 15:50 Dendritic cells and combinatorial adjuvants reprogram TME and lymphoid tissues for  
enhanced effectiveness of PD1 blockade, *Pawel Kalinski*

15:50 16:05 Next generation strategies to target MAPK signaling in cancer, *Poulikos Poulikakos*

16:05 16:35 Discussion LIVE

16:35 16:50 Putting it all together – Practical Considerations for Monday Clinic, *Sanjiv S. Agarwala*

16:50 17:00 Conclusions, *Paolo A. Ascierto, Corrado Caracò, Iman Osman, Igor Puzanov*



**3P Solution S.r.l.** a socio unico.

Sede Legale: Corso Magenta 81, 20123 Milano.

Capitale sociale: 10.000,00€ iv. P.IVA/CF 06860060968 Iscrizione REA MI n.1919426.

Provider Standard n. 327 dal 15 ottobre 2012 - Sistema di gestione per la qualità secondo la Norma

UNI EN ISO 9001:2015 per progettazione ed erogazione dei servizi per la Formazione Continua in Sanità.

Certificazione CSQA n. 23887

### **PRESIDENCY**

**Paolo A. Ascierto** - Director, Medical Oncology, Melanoma, Cancer Immunotherapy and Development Therapeutics Department, National Cancer Institute “Fondazione G. Pascale”, Naples, Italy

**Corrado Caracò** - Director of Melanoma and Skin Tumor Surgery, National Cancer Institute “Fondazione G. Pascale”, Naples, Italy

**Iman Osman** - Rudolf L. Baer MD Professor of Dermatology, Professor, Departments of Medicine (Oncology) and Urology, Director, Interdisciplinary Melanoma Program, Associate Dean for Translational Research Support, New York University Langone, Medical School, New York, NY, US

**Igor Puzanov** - Senior Vice President, Clinical Investigations Director, Center of Early Phase Clinical Trials, Chief, Melanoma Section, Roswell Park Comprehensive Cancer Center, Developmental Therapeutics Buffalo, NY, US

### **SCIENTIFIC BOARD**

**Sanjiv S. Agarwala** - Professor & Chief, Haematology & Oncology, St Luke’s University Hospital and Temple University, Bethlehem, PA, US

**Paolo A. Ascierto** - Director, Medical Oncology, Melanoma, Cancer Immunotherapy and Development Therapeutics Department, National Cancer Institute “Fondazione G. Pascale”, Naples, Italy

**Carlo Bifulco** - Medical Director, PSJH System Genomics Laboratory, Providence St. Joseph Health, Director and Member, Translational Molecular Pathology, Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, US

**Lisa H. Butterfield** - Research Center Vice President, Parker Institute for Cancer Immunotherapy and Adjunct Professor of Microbiology and Immunology, University of California, San Francisco, CA, US

**Elizabeth M. Burton** - Director, Melanoma Research Planning & Development, The University of Texas MD Anderson Cancer Center, Houston, TX, US

**Corrado Caracò** - Director of Melanoma and Skin Tumor Surgery, National Cancer Institute “Fondazione G. Pascale”, Naples, Italy

**Mary Dean** - Executive Director, Society of ImmunoTherapy for Cancer (SITC), Milwaukee, WI, US

**Sandra Demaria** - Professor of Pathology and Laboratory Medicine, Professor of Radiation Oncology and Adjunct Professor at Department of Pathology, Weill Cornell Medical College and NYU School of Medicine, New York City, NY, US



**Reinhard Dummer** - Professor of Dermatology, University of Zurich Hospital, Department of Dermatology, Zurich, Switzerland

**Bernard A. Fox** - Chief of Molecular and Tumor Immunology Laboratory, Robert W. Franz Cancer Research Center - Earle A. Chiles Research Institute, Providence Cancer Center, Portland, OR, US

**Jerome Galon** - INSERM Laboratory of Integrative Cancer Immunology; Team labeled League Against Cancer; Cordeliers Research Center, Sorbonne University, University of Paris, Paris, France

**Claus Garbe** - Professor of Dermatology, President of the European Association of DermatoOncology (EADO), Center for Dermatooncology, Department of Dermatology, Eberhard Karls University, Tuebingen

**Omid Hamid** - Chief of Research/ Immuno-Oncology and Co-Director, Cutaneous Malignancy Program, The Angeles Clinic and Research Institute, Los Angeles, CA, US

**Patrick Hwu** - President & CEO, Moffitt Cancer Center, Tampa, FL, US

**Giuseppe Masucci** - M.D., Associate Professor, Department of Oncology-Pathology and KcRN, Karolinska Institutet, Cancer Centrum Karolinska (CCK), Karolinska University Hospital, Stockholm, Sweden

**Olivier Michielin** - Head of Precision Oncology Center and melanoma clinic, Oncology Department, Lausanne University Hospital (CHUV), Lausanne, Switzerland

**Iman Osman** - Rudolf L. Baer MD Professor of Dermatology, Professor, Departments of Medicine (Oncology) and Urology, Director, Interdisciplinary Melanoma Program, Associate Dean for Translational Research Support, New York University Langone, Medical School, New York, NY, US

**Giuseppe Palmieri** - President, Italian Melanoma Intergroup (IMI), Head of Unit of Cancer Genetics, Institute of Biomolecular Chemistry (ICB), National Research Council (CNR), Sassari, Italy

**Michael A. Postow** - Memorial Sloan Kettering Cancer Center, New York, NY, US

**Igor Puzanov** - Senior Vice President, Clinical Investigations Director, Center of Early Phase Clinical Trials, Chief, Melanoma Section, Roswell Park Comprehensive Cancer Center, Developmental Therapeutics Buffalo, NY, US

**Magdalena Thurin** - Program Director, Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, NCI, NIH, Rockville, MD, US

**Tara Withington** - Executive Director Emeritus, Society of ImmunoTherapy for Cancer (SITC), Milwaukee, WI, US

